Physician profile
Amy Smith
NPI 1750617817
$3,186.22
in general payments reported to CMS, 2019-2025
28 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.41 · 2022: $1,605 · 2023: $1,140 · 2024: $306 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.57 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $434.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $426.47 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $295.62 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.08 | 2022-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $155.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $141.65 | 2022-2023 | Austedo, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $139.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $139.46 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $137.90 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.90 | 2022-2024 | Jardiance |
| Abbvie INC. | $127.74 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.51 | 2022-2023 | Trintellix |
| Amgen INC. | $105.86 | 2022-2024 | Repatha, Otezla, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $105.46 | 2022-2024 | |
| Corcept Therapeutics | $84.19 | 2023 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.35 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $42.42 | 2022 | |
| Exact Sciences Corporation | $40.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cequr Corporation | $38.06 | 2022-2023 | Cequr Simplicity |
| Abbott Laboratories | $33.11 | 2022 | |
| Heartflow, INC. | $31.35 | 2022 | |
| Optinose US, INC. | $24.92 | 2023 | |
| Amarin Pharma, INC. | $20.06 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.53 | 2025 | Fanapt |
| Eisai INC. | $17.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.58 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.